OMB APPROVAL
--------------------------
OMB Number: 3235-0145
Expires: December 31, 2005
Estimated average burden
hours per response......11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 2)*
LIGAND PHARMACEUTICALS INCORPORATED
--------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, $.001 PAR VALUE
--------------------------------------------------------------------------------
(Title of Class of Securities)
53220K207
--------------------------------------------------------------------------------
(CUSIP Number)
October 3, 2002
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
PERSONS WHO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS FORM ARE
NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB CONTROL
NUMBER.
SEC 1745 (12-02)
Page 1 of 5 Pages
CUSIP NO. 53220K207
--------------------------------------------------------------------------------
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Eli Lilly and Company
35-0470950
--------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) [ ]
-----------------------------------------------------------------
(b) [ ]
-----------------------------------------------------------------
Not Applicable
--------------------------------------------------------------------------------
3. SEC Use Only
--------------------------------------------------------------------------------
4. Citizenship or Place of Organization
Indiana
--------------------------------------------------------------------------------
Number of 5. Sole Voting Power
Shares 2,849,964
-----------------------------------------------------
Beneficially 6. Shared Voting Power
Owned by None
-----------------------------------------------------
Each 7. Sole Dispositive Power
Reporting 2,849,964
-----------------------------------------------------
Person With: 8. Shared Dispositive Power
None
--------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person
2,849,964
--------------------------------------------------------------------------------
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)
Not Applicable
--------------------------------------------------------------------------------
11. Percent of Class Represented by Amount in Row (9)
3.99%
--------------------------------------------------------------------------------
12. Type of Reporting Person (See Instructions)
CO
--------------------------------------------------------------------------------
Page 2 of 5 Pages
Item 1(a). Name of Issuer:
Ligand Pharmaceuticals Incorporated
Item 1(b). Address of Issuer's Principal
Executive Offices:
10275 Science Center Drive
San Diego, CA 92121
Item 2(a). Name of Person Filing:
Eli Lilly and Company
Item 2(b). Address of Principal Business
Office or, if None, Residence:
Lilly Corporate Center
Indianapolis, IN 46285
Item 2(c). Citizenship:
Indiana
Item 2(d). Title of Class of Securities:
Common Stock, $.001 Par Value
Item 2(e). CUSIP Number:
53220K207
Item 3. If this statement is filed pursuant to Rule
13d-1(b), or 13d-2(b) or (c), check whether the
person filing is a:
(a)-(j) Not applicable
If this statement is filed pursuant to Rule 13d-1(c),
check this box. [ X ]
Item 4. Ownership.
(a) Amount Beneficially Owned:
2,849,964
Page 3 of 5 Pages
(b) Percent of Class:
3.99% (based on outstanding shares at
October 31, 2002)
(c) Number of shares as to which the person has:
Sole voting power 2,849,964
Shared voting power None
Sole dispositive power 2,849,964
Shared dispositive power None
Item 5. Ownership of Five Percent or Less of a Class. [ X ]
Item 6. Ownership of More Than Five Percent on Behalf of
Another Person.
Not applicable
Item 7. Identification and Classification of the Subsidiary
which Acquired the Security Being Reported on by the
Parent Holding Company.
Not applicable
Item 8. Identification and Classification of Members of the
Group.
Not applicable
Page 4 of 5 Pages
Item 9. Notice of Dissolution of Group.
Not applicable
Item 10. Certifications.
By signing below, I certify that, to the best of my
knowledge and belief, the securities referred to above were
not acquired and are not held for the purpose of or with the
effect of changing or influencing control of the issuer of
the securities and were not acquired and are not held in
connection with or as a participant in any transaction
having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
ELI LILLY AND COMPANY
By: /s/ Charles E. Golden
---------------------------------
Charles E. Golden
Executive Vice President and
Chief Financial Officer
Date: February 13, 2003
Page 5 of 5 Pages